BioPharma Dive September 8, 2025
Clinical trial data presented this weekend show drugs from Takeda, Alkermes and Eisai significantly helped people with narcolepsy, heralding a new era of sleep medicine.
Drug developers from around the world rang in a new era of sleep medicine Monday, as data from a series of clinical trials show narcolepsy can be effectively treated by amplifying a specific brain protein.
That protein, called orexin-2, helps regulate important body functions like appetite, arousal and wakefulness, which has in turn made it a promising target for drug companies. Johnson & Johnson, for instance, hopes that by blocking orexin-2, its experimental medicine seltorexant can be used to combat insomnia in patients with major depression.
More commonly, though, developers are looking to boost this...
Today's Sponsors
Today's Sponsor